ISIN:DE000A3DSV01

EQS-News: Cantourage Group SE verzeichnet deutliches Umsatzwachstum in den ersten neun Monaten 2023 und bestätigt Gesamtjahresprognose

Retrieved on: 
Donnerstag, Dezember 14, 2023
Unternehmen, Welt, Ergebnis, Vertrieb, Prognose, Isin, Patient, Gruppe, Rezept, Partnerschaft, Million, Markt, Karat, Weg, Fokus, Freigabe, Prozentzeichen, Rechnung, Monat, Basis, Entwicklung, Business Development, Meilenstein, Sumō, Vasco, Green, Start, Track, Gesellschaft, Umsatz, Steigerung, Produzent, Arzneimittel, EBITDA, Optimum, Anstieg, Erwartung, SE, Effekt, Versorgung, Quartal, Produktion, Bitcoin, Crypto, ISIN, Internet, Hanf

EQS-News: Cantourage Group SE records significant revenue growth in the first nine months of 2023 and confirms full-year forecast

Retrieved on: 
Mittwoch, Dezember 13, 2023
Partnership, Telehealth, VASCO, GHA, Cannabis, EUR, EBITDA, Patient, CFO, ISIN, 2008 sumo cannabis scandal, Drug

In the third quarter of 2023 revenue increased to EUR 6.1 million* (Q3 2022: EUR 3.4 million*).

Key Points: 
  • In the third quarter of 2023 revenue increased to EUR 6.1 million* (Q3 2022: EUR 3.4 million*).
  • Based on the expectations for the current quarter, Cantourage continues to expect to achieve its forecast for the full year 2023.
  • Bernd Fischer, CFO of Cantourage, states: "Our business development was successful in the first nine months of 2023.
  • As a result of this and cost-saving measures, we expect to achieve our forecast business development for 2023 as planned."

EQS-News: Cantourage Group SE: NuWays confirms 'Buy' recommendation

Retrieved on: 
Donnerstag, Oktober 26, 2023
ISIN, EUR, Research, Cryptocurrency

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful.
  • The important notices at the end of this press release should be observed.
  • Berlin, October 25, 2023 – In a research update published today, the research house NuWays AG, Hamburg, once again rates the shares of Cantourage Group SE (hereinafter "Cantourage", ISIN: DE000A3DSV01, www.cantourage.com/en ) with a "Buy" recommendation and a price target of EUR 12.50.

EQS-News: Montega AG includes Cantourage Group SE in its coverage with 'Buy'

Retrieved on: 
Donnerstag, Oktober 26, 2023
EUR, ISIN, Cryptocurrency

Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful.

Key Points: 
  • Not for publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such publication or distribution would be unlawful.
  • The important notices at the end of this press release should be observed.
  • Berlin, October 20, 2023 – Research house Montega AG, Hamburg, initiated coverage on Cantourage Group SE (hereinafter "Cantourage", ISIN: DE000A3DSV01, www.cantourage.com/en ) in a report published yesterday.
  • Montega rates the Cantourage share with a "buy" recommendation and a price target of EUR 10.50.

EQS-News: Cantourage Group SE launches a range of high-THC medicinal cannabis flowers in Switzerland together with Astrasana

Retrieved on: 
Donnerstag, Oktober 26, 2023
Flower, LOT, Still Breathing (Green Day song), Partnership, THC, GMP, Patient, Drug

Berlin, October 24, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading European company for the production and distribution of medical cannabis, has signed a long-term supply agreement for medical cannabis with the Swiss cannabis company Astrasana.

Key Points: 
  • Berlin, October 24, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading European company for the production and distribution of medical cannabis, has signed a long-term supply agreement for medical cannabis with the Swiss cannabis company Astrasana.
  • To start with, patients in Switzerland will be able to obtain medical cannabis flowers from the growers LOT 420, Green Karat and Breathing Green from Canada.
  • This represents a significant step for Astrasana and a milestone in the supply of medical cannabis in Switzerland.
  • The partnership with Cantourage marks a significant development for the supply of medical cannabis in Switzerland.

EQS-News: Cantourage Group SE: Cantourage shortlisted for European Small and Mid-Cap Awards 2023

Retrieved on: 
Montag, September 25, 2023
IPO, European Small and Mid-Cap Awards, Civil service commission, Innovation, EuropeanIssuers, Federation, Cannabis, ISIN, European Commission, Cryptocurrency

Cantourage nominated for "Star of Innovation" category; this recognizes companies that put innovation at the core of their strategy

Key Points: 
  • Cantourage nominated for "Star of Innovation" category; this recognizes companies that put innovation at the core of their strategy
    Winners of the competition will be announced on November 14, 2023 in Bilbao, Spain
    Berlin, September 25, 2023 – Cantourage Group SE (hereinafter "Cantourage", ISIN: DE000A3DSV01, www.cantourage.com ), a leading European producer and distributor of medical cannabis, has made it onto the shortlist and thus into the narrowest group of candidates for the 11th European Small and Mid-Cap Awards 2023.
  • The awards were introduced by the European Commission in 2013 and recognize listed European companies in four different categories.
  • Co-organizers are EuropeanIssuers, a European association of listed companies, and the Federation of European Securities Exchanges (FESE).
  • Philip Schetter, CEO of Cantourage, comments "We are delighted to be shortlisted for the European Small and Mid-Cap Awards.